Omeros Corporation (3O8)
Summary
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros Corporation (OMER) Q2 2026 Earnings Call Transcript
Omeros Q2 Earnings Call Highlights
Omeros NASDAQ: OMER reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or TA-TMA, as the company generated positive operating cash flow and reduced its convertible debt after the quarter ended.
Omeros Corporation (3O8) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Omeros Corporation ever had a stock split?
Omeros Corporation Profile
| Biotechnology Industry | Healthcare Sector | Gregory A. Demopulos CEO | XMUN Exchange | US6821431029 ISIN |
| US Country | 175 Employees | - Last Dividend | 2 Oct 2009 Last Split | 8 Oct 2009 IPO Date |
Overview
Omeros Corporation is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of therapeutic products for a wide range of medical disorders. Founded in 1994 and based in Seattle, Washington, the company focuses on delivering innovative treatments for immunologic diseases, cancers, and conditions related to addiction and compulsive disorders. By targeting small-molecule and protein therapeutics, and specializing in orphan indications, Omeros is dedicated to addressing unmet medical needs, particularly in areas where treatment options are limited or non-existent.
Products and Services
- Narsoplimab (OMS721/MASP-2)
A pivotal clinical trial has been completed for Narsoplimab, a therapeutic candidate aimed at treating hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA). Additionally, it is undergoing a Phase III clinical trial for patients with immunoglobulin A nephropathy (IgAN) and a Phase II clinical trial to assess its efficacy in treating COVID-19.
- OMS1029
This long-acting, second-generation antibody is in Phase I clinical trials. It targets lectin pathway disorders, showcasing Omeros' commitment to addressing areas with significant unmet medical needs.
- OMS906
Currently, OMS906 has completed Phase II clinical trials. This product candidate is designed for the treatment of Paroxysmal nocturnal hemoglobinuria (PNH), complement 3 glomerulopathy (C3G), and other disorders associated with the alternative pathway of the complement system.
- OMS527
In Phase I clinical trials, OMS527 is being developed for the treatment of addictions and compulsive disorders, alongside movement disorders, demonstrating Omeros' foray into neurological conditions with significant impact on public health.
- Preclinical Development Programs
The company is also pursuing several ambitious preclinical development programs. These include MASP-2, targeting lectin pathway disorders; MASP-3 small-molecule inhibitors aimed at alternative pathway disorders; and a diverse array of immunotherapies such as Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for various cancers. These cutting-edge scientific endeavors highlight Omeros Corporation's dedication to pioneering treatments for complex conditions and diseases.
